Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Conditions:   Lymphoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Melanoma;   Metastatic Renal Cell Cancer;   Recurrent Bladder Carcinoma;   Recurrent Classical Hodgkin Lymphoma;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Renal Cell Carcinoma;   Stage III Bladder Cancer;   Stage III Lymphoma;   Stage III Non-Small Cell Lung Cancer AJCC v7;   Stage III Renal Cell Cancer;   Stage III Skin Melanoma;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIA Skin Melanoma;   Stage IIIB Non-Small Cell Lung Cancer AJCC v7;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Bladder Cancer;   Stage IV Lymphoma;   Stage IV Non-Small Cell Lung Cancer AJCC v7;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Bladder Cancer;   Stage IVB Bladder Cancer;   Unresectable Head and Neck Squamous Cell Carcinoma;   Unresectable Solid Neoplasm
Interventions:   Drug: Enzyme Inhibitor Therapy;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Pembrolizumab
Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
Not yet recruiting - verified July 2017

from # All Medicine by Alexandros G. Sfakianakis via alkiviadis.1961 on Inoreader http://ift.tt/2gZFTUs